Business
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California,.
About this update from Better Home & Finance Holding Company
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California, during JPM Week.","length":561,"tagName":"p"},{"type":"text","content":"The YAFO Capital Access Asia Partnering Forum brings together innovative life science companies and leading investors, pharmaceutical partners, and strategic advisors, with a particular focus on fostering collaboration between North American and Asian capital and industry partners.","length":282,"tagName":"p"},{"type":"text","content":"In addition to the YAFO Capital event on January 11th, Dr. Ahmad Doroudian Chief Executive Officer, will attend the following events:","length":133,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H7 Life science Investment Forum & China Night Reception on January 12th,","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"WuXi Global Forum 2026 on January 13th, and","length":43,"tagName":"p"}]},{"val":[{"type":"text","content":"DARPA and Ferocity Capital Biodefence Summit on January 13th.","length":61,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":181,"olType":false},{"type":"text","content":"Dr. Ahmad Doroudian will represent BetterLife and will be available for one-on-one meetings with investors, potential partners, and other stakeholders to discuss the Company's development strategy for BETR-001.","length":214,"tagName":"p"},{"type":"text","content":"Parties interested in scheduling a meeting with BetterLife during the YAFO Capital Access Asia Partnering Forum are encouraged to contact Dr. Ahmad Doroudian at the email address below.","length":185,"tagName":"p"},{"type":"text","content":"BETR-001, a potent neuroplastogen, is BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, post traumatic stress disorder and cluster he...